Curative Biosciences

Curative Biosciences Current Liabilities

The Current Liabilities of Curative Biosciences (CBDX) as of Oct 30, 2026 is 643,165.00 USD. In the previous year, Current Liabilities was 630,318.00 USD — a change of 2.04% (higher).

Current Liabilities

643,165.00USD

YoY

2.04%

Last updated:

Current Liabilities of Curative Biosciences is 2017 643,165.00 USD. Current Liabilities of Curative Biosciences was 2016 630,318.00 USD. It decreases by 2.04% higher compared to the previous year.

The Curative Biosciences Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2010
180,000.00 USD
Jan 1, 2011
430,000.00 USD
Jan 1, 2012
484,800.00 USD
Jan 1, 2013
670,900.00 USD
Jan 1, 2014
313,950.00 USD
Jan 1, 2015
548,227.00 USD
Jan 1, 2016
630,318.00 USD
Jan 1, 2017
643,165.00 USD
The Curative Biosciences Current Liabilities history
YEARCurrent LiabilitiesYoY
643,165.00USD+2.04%
630,318.00USD+14.97%
548,227.00USD+74.62%
313,950.00USD-53.20%
670,900.00USD+38.39%
484,800.00USD+12.74%
430,000.00USD+138.89%
180,000.00USD-18.18%
220,000.00USD-31.25%
320,000.00USD-37.25%
510,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curative Biosciences Stock analysis

What does Curative Biosciences do? Curative Biosciences Inc is a biotechnology company specializing in the development of innovative therapies for serious diseases. The company was founded in 2011 by a group of experienced scientists, medical experts, and entrepreneurs and is based in San Francisco, California. History Curative Biosciences Inc aims to develop groundbreaking therapies for diseases that currently have no effective treatment options. The company has had an impressive track record in recent years, as evidenced by numerous awards and recognition from reputable institutions and media. Business Model Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. The company conducts intensive research to identify and develop promising drug candidates. Divisions Curative Biosciences Inc has focused on several divisions to offer a wide range of innovative therapy options: - Oncology: Curative Biosciences Inc has developed a portfolio of drug candidates that specifically target malignant tumors without damaging healthy tissue. - Autoimmune diseases: The company has also developed some promising drug candidates for autoimmune diseases that regulate the immune system and reduce the risk of side effects and complications. - Neurodegenerative diseases: Curative Biosciences Inc is intensively working on the development of therapies against neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Products The company has already developed several promising products that are currently in clinical trials. Here are some examples: - CB-01: A drug candidate specifically developed to target aggressive tumors such as lung cancer, pancreatic cancer, and leukemia. - CB-02: A drug candidate that regulates the immune system and could be used in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. - CB-03: A promising drug candidate against Alzheimer's disease that reduces β-amyloid proteins in the brain and could slow down the progression of the disease. Summary Curative Biosciences Inc is an emerging biotechnology company specializing in the development of innovative therapies for serious diseases. The company conducts intensive research and has already developed several promising drug candidates that are currently in clinical trials. Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. Curative Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curative Biosciences stock

Current Liabilities of Curative Biosciences is 643,165.00 USD in 2017.

Current Liabilities of Curative Biosciences changed from 630,318.00 USD to 643,165.00 USD, representing a 2.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Curative Biosciences since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Curative Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Curative Biosciences

All Key Metrics — Curative Biosciences